LENZ
LENZ Therapeutics, Inc.NASDAQHealthcare$9.67+3.42%ClosedMarket Cap: $303.2M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.06
P/S
15.88
EV/EBITDA
-3.14
DCF Value
$2.41
FCF Yield
-23.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.2%
Operating Margin
-477.5%
Net Margin
-430.3%
ROE
-37.5%
ROA
-26.8%
ROIC
-32.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $1.6M | $-35.9M | $-1.16 |
| FY 2025 | $19.1M | $-82.1M | $-2.85 |
| Q3 2025 | $12.5M | $-16.7M | $-0.59 |
| Q2 2025 | $5.0M | $-14.9M | $-0.53 |
Analyst Ratings
View AllCitigroupBuy
2026-03-26B of A SecuritiesBuy
2026-03-25Raymond JamesOutperform
2025-10-20Piper SandlerOverweight
2025-10-10CitigroupBuy
2025-08-01Trading Activity
Insider Trades
View AllChevallard Daniel R.officer: Chief Financial Officer
BuyMon Mar 30
Schimmelpennink Evert B.director, officer: President, CEO and Secretary
BuyMon Mar 30
George Jeffrey P.director
BuyMon Mar 30
Odrich Marcofficer: Chief Medical Officer
SellTue Jan 06
Chevallard Daniel R.officer: Chief Financial Officer
SellTue Jan 06
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.29
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.